Diagens (02526.HK) was listed on March 30, 2026. As the "first medical imaging LLM stock" on the HKEX, its share price soared over 200% within two weeks, closing at HKD 300 on April 10. The company’s core product, AI AutoVision®, is the first chromosome karyotype analysis system in China to receive the "Class III Innovative Medical Device" designation, improving analysis efficiency by approximately 12 times. It currently holds a 30.6% market share, ranking first in the country. In 2025, total revenue was approximately RMB 164 million (+133.72%), while the net loss expanded to RMB 67.14 million. The company's market capitalization has surpassed HKD 24 billion, with a price-to-sales (P/S) ratio exceeding 130x, far beyond the industry average.
NewTimeSpace News, Zixin Group announced on April 13 that its wholly-owned subsidiary has established a joint venture company, Zixin Fresh, with AANDJ Group to enter the fresh agricultural products distribution business in Singapore and neighboring Southeast Asian countries.
NewTimeSpace News, according to an announcement disclosed on the Singapore Exchange, Telix announced on April 13 that it has entered into a strategic collaboration with Regeneron to jointly develop and commercialize next-generation radiopharmaceutical therapies under a 50/50 cost and profit-sharing model.
NewTimeSpace News, CapitaLand Investment announced on April 13 that its Asia Pacific Credit Program II has achieved final close, with total equity commitments of US$320 million and adding approximately US$600 million to funds under management.
NewTimeSpace News: Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (03378.HK) announced that four innovative drug research results of the Company will be displayed in the form of posters at the 2026 Annual Meeting of the American Association for Cancer Research (AACR), covering R&D pipelines including HX044, HX116, HX112 and the 3D tumor organoid ADC evaluation system.
On April 9, 2026, GenFleet Therapeutics (02595.HK) announced that its KRAS G12D inhibitor GFH375 received Breakthrough Therapy Designation (BTD) from the CDE, causing its stock price to surge 9.05% against the market trend. The drug has launched the world's first Phase III registrational study for an oral inhibitor and holds FDA Fast Track status. In 2025, the company reported revenue of RMB 130 million (+24.4% YoY). Due to fair value changes in redemption liabilities, the book net loss widened to RMB 1.795 billion, though the adjusted net loss narrowed to RMB 227 million. Its first commercial product, GFH925, saw weak early sales and faces intense global competition from over 20 rival candidates.
NewTimeSpace News, according to an announcement released on the Singapore Exchange on April 9, CDL has established a S$2 billion multicurrency perpetual securities issuance programme. United Overseas Bank Limited has been appointed as the arranger and dealer of the programme.
NewTimeSpace News, Marco Polo Marine (Singapore) announced on April 9 that it has issued 177,000 new shares at an exercise price of S$0.067 per share pursuant to the exercise of options granted under the 2024 Employee Share Option Scheme. The new shares will be listed and quoted on the SGX-ST on April 10.
NewTimeSpace News, according to an announcement released on the Singapore Exchange on April 9, Tata Steel completed the acquisition of the remaining 0.01% stake in its subsidiary TSCPL, making TSCPL its indirect wholly-owned subsidiary.
NewTimeSpace News, April 10,Telix Pharmaceuticals announced that the U.S. FDA has accepted its resubmitted New Drug Application (NDA) for Pixclara® (TLX101-Px), an investigational PET agent for glioma imaging, and has assigned a PDUFA goal date of September 11, 2026.
NewTimeSpace News: Peijia Medical Limited (09996.HK) announced the successful completion of the first patient implant in the US FDA early feasibility study of the GeminiOne® Transcatheter Edge-to-Edge Repair (TEER) System.The procedure was performed by Professor Saibal Kar, Clinical Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles.
SAINT BELLA Group (02508.HK) recently released its first full annual report for 2025, with revenue reaching RMB 1.046 billion (+31.0%) and adjusted net profit at RMB 125 million. Despite the flagship brand’s ASP rising to RMB 267,000 and the company’s intensive recent positioning in AI LLMs and embodied intelligence funds, its stock performance remains weak. As of April 8, 2026, it closed at HKD 4.11, down approximately 37.54% from its issue price. Even as the leader in the high-end market, SAINT BELLA must still prove to investors its "anti-cyclical" ability to maintain long-term profitability amidst a service-intensive model and its transition into the AI space.
NewTimeSpace News, April 8,CICT announced the novation of existing electric vehicle charging station service contracts for its properties, including Clarke Quay, Plaza Singapura, Raffles City Singapore, Funan and Westgate, from TotalEnergies Charging Services Singapore Pte. Ltd. to SP Mobility.
NewTimeSpace News, April 8,Samudera Shipping announced the launch of a new weekly container service, the "Korea-Japan Shuttle" (KJS), connecting Japan and South Korea.
NewTimeSpace News, April 8,Geo Energy announced that the company has issued and allotted 750,000 new shares, pursuant to the exercise of options under its share option scheme.
NewTimeSpace News, April 8,Seatrium announced that the company and its subsidiary, Seatrium Financial Services, have established a S$3 billion multicurrency debt issuance programme.
